Abstract:BACKGROUND: To analyze the main reasons for screening failure in the screening process of healthy subjects in phase I clinical trials and coping strategies.METHODS: We retrospectively collected data from the screening process of 1,640 healthy subjects in 12 phase I clinical trials conducted between April 2019 and July 2020 at the First Affiliated Hospital of Bengbu Medical College. The reasons for screening failure were statistically analyzed (χ2 test), and correlation studies were conducted to explore the main factors associated with screening failure.RESULTS: Among the 1,640 healthy subjects, 632 (38.5%) successfully passed screening, and 1,008 (61.5%) failed screening. Abnormal laboratory test results (43.25%), abnormal vital sign examination results (11.81%), withdrawal of informed consent (10.02%), abnormal height/weight examination results (8.33%), and abnormal electrocardiogram (ECG) examination results (5.66%) accounted for 79.07% of the screening failures. Subjects aged 46-57 years were more likely to fail screening than those aged 18-30 or 31-45 years (158/220 vs. 541/893 vs. 309/527, respectively, P=0.002), and males were more likely than females to fail screening (721/1, 133 vs. 287/507, respectively, P=0.007). However, the distance between the subject's residence and clinical trial institution (P=0.491) was not significantly correlated with screening failure.CONCLUSIONS: Before trial screening, healthy subjects should be informed of the clinical trial risks and have sufficient time to consider or discuss participation with their family members. In addition, subjects should be informed that they should eat lightly, have adequate rest, and maintain a relaxed state of mind prior to screening. Regarding fluctuations in the normal range of laboratory indicators and ECG examination reports during the screening process, clinicians should determine the medical decision level (MDL) for each indicator. If no clinical significance is identified, then the subject can be included. In terms of sex and age, this study provides reasonable suggestions to further improve project protocols and improve the healthy subject screening success rate.

Discussion on the management model of subject screening and reasonable application of subject databases in phase Ⅰclinical trials in China

Phased subjects management strategy of phaseⅠclinical trials for new drug

Construction of data remote monitoring and auditing system for clinical trials

Protection of Human Rights in Clinical Trials

Design and Establishment for the Database of Clinical Research in the Service of Modern Medical Conditions Treated by Acupuncture

Analysis of the reasons for screening failure in phase I clinical trials in China: a retrospective study of the clinical trials screening process

Analysis of the Registration of Radiological Clinical Trials and Hints for Science Research Management

Discussion on the construction of management system for clinical trial investigators

Discussion on management function in clinical trials of hospital drug clinical trial institution

Study on the key steps for the subject medication of phase Ⅰ clinical trials

Management of clinical trial drugs in our institution

Discussion of Establishment of Standardized Clinical Trial Management System for Anti-tumor Drugs in Cancer Hospital

Discussion on management of new drug clinical trials proj'ect

Discussion of building a platform for the qualification of certification management about the drug clinical trials

Improving the management level of clinical trial based on the establishment of drug clinical trial center pharmacy

Discussion on the management mode of real-time reimbursement of testing expense in clinical trials

Analysis and discussion on the subject complaint in clinical drug trials

A Clinical Trial Model Based on Internet Platform

Human Subjects Protections in Clinical Drug Trials in China

Incorporating Historical Information to Improve Phase I Clinical Trials

Ethical management of human clinical research in the age of big data